NCT02342418View on ClinicalTrials.gov

Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
Obesity
Interventions
DRUG

Tedizolid phosphate

Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Amit.Pai

OTHER

NCT02342418 - Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults | Biotech Hunter | Biotech Hunter